Krystal Biotech (KRYS) Stock Overview
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for KRYS from our risk checks.
KRYS Community Fair Values
Create NarrativeSee what 58 others think this stock is worth. Follow their fair value or set your own to get alerts.
The Rare Disease Rocket Ship
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Krystal Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$258.81 |
| 52 Week High | US$298.30 |
| 52 Week Low | US$122.80 |
| Beta | 0.48 |
| 1 Month Change | -7.32% |
| 3 Month Change | 20.34% |
| 1 Year Change | 50.62% |
| 3 Year Change | 236.51% |
| 5 Year Change | 269.20% |
| Change since IPO | 2,332.42% |
Recent News & Updates
Recent updates
The Rare Disease Rocket Ship
Krystal Biotech reports tomorrow, February 17, 2026. The narrative is no longer about survival; it’s about dominance.Krystal Biotech: KB707 Program Bolstered By RMAT And 2nd Half 2026 Update
Feb 10Investors Shouldn't Be Too Comfortable With Krystal Biotech's (NASDAQ:KRYS) Earnings
Nov 10
Market Participants Recognise Krystal Biotech, Inc.'s (NASDAQ:KRYS) Earnings Pushing Shares 29% Higher
Oct 09Why We're Not Concerned Yet About Krystal Biotech, Inc.'s (NASDAQ:KRYS) 26% Share Price Plunge
May 23Should You Be Adding Krystal Biotech (NASDAQ:KRYS) To Your Watchlist Today?
Apr 21Krystal Biotech Soars As Q4 Earnings Put Blockbuster Commercialization In Focus
Feb 21Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On
Oct 14
Expanding Global Reach With VYJUVEK Set To Skyrocket Revenue And Sharpen Market Edge
International expansion and upcoming product launches indicate significant potential for revenue growth and market diversification.Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)
Jul 31Krystal Biotech's Future Brightens With Vyjuvek's Robust Launch
Feb 28Krystal Biotech: Ready For Launch
Feb 20Shareholder Returns
| KRYS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.7% | 1.2% | -0.6% |
| 1Y | 50.6% | 28.8% | 15.5% |
Return vs Industry: KRYS exceeded the US Biotechs industry which returned 28.8% over the past year.
Return vs Market: KRYS exceeded the US Market which returned 15.5% over the past year.
Price Volatility
| KRYS volatility | |
|---|---|
| KRYS Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KRYS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: KRYS's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 295 | Krish Krishnan | www.krystalbio.com |
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb.
Krystal Biotech, Inc. Fundamentals Summary
| KRYS fundamental statistics | |
|---|---|
| Market cap | US$8.06b |
| Earnings (TTM) | US$204.83m |
| Revenue (TTM) | US$389.13m |
Is KRYS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KRYS income statement (TTM) | |
|---|---|
| Revenue | US$389.13m |
| Cost of Revenue | US$23.05m |
| Gross Profit | US$366.08m |
| Other Expenses | US$161.25m |
| Earnings | US$204.83m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.01 |
| Gross Margin | 94.08% |
| Net Profit Margin | 52.64% |
| Debt/Equity Ratio | 0% |
How did KRYS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/02 05:36 |
| End of Day Share Price | 2026/03/02 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Krystal Biotech, Inc. is covered by 20 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Caroline Palomeque | Berenberg |
| Alec Stranahan | BofA Global Research |
| Justin Zelin | B. Riley Securities, Inc. |